The Ameliorative Effects of GLP-1RA on Diabetic Cardiac Autonomatic Neuropathy
- Status
- RecruitingResults none
- Why it is watched
- non-weight indication: cardiovascular
- Who it enrolls
- age 18 Years to 70 Years; no BMI minimum stated; conditions: Type 2 Diabetes; Diabetes With Diabetic Autonomic Neuropathy (Diagnosis)
- Interventions
- Glucagon-like peptide-1 receptor agonist：Semaglutide
- Conditions
- Type 2 Diabetes; Diabetes With Diabetic Autonomic Neuropathy (Diagnosis)
- Phase and size
- Phase 4 · 50 participants
- Dates
- Start 2024-06-13
Primary completion 2026-12-31 - Sponsor
- The First Affiliated Hospital with Nanjing Medical University (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- heart rate variability（HRV）baseline and 12 weeks later
02Eligibility
Who can take part
Inclusion Criteria: 1. Patients aged 18-70 years 2. Patients with T2DM who meet the diagnostic guidelines 3. The patient signed the relevant informed consent form 4. Being overweight or obese Exclusion Criteria: 1. \<18 years old 2. Pregnant or lactating women 3. Acute and chronic pancreatitis 4. Recent acute complications of diabetes 5. Arrhythmia or taking drugs that affect heart rate 6. Thyroid disease 7. Severe organ dysfunction 8. Denial of informed consen
03Change log
Registry changes
No changes recorded since the trial was added.